الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 132 |  |  |
| | | from | 132 | | |
Abstract
An ideal stent should seal intimal flaps and optimize lumen size with radial strength to resist acute vessel recoil, and at a later stage would be fully resorbed, leading to restoration of the vessel’s biological properties.
It should control restenosis by limiting negative remodeling and by controlling excessive healing by delivery of an antiproliferative drug. Beyond 6 months, a permanent implant has no useful function and has possible disadvantages including the potential for late thrombosis. The concept of a stent that does its job and disappears has appeal. (Waksman, 2006).A number of different materials ranging from magnesium to a variety of polymers have been used to construct stents of different designs. Some of these are being tested in clinical trials. One of the best outcomes to date has been with the BVS everolimus-eluting PLLA stent where in the Absorb trial, cohort A at 2 years, the stent was safe in the small number of patients with simple lesions. Indeed, there is luminal enlargement between 6 months and 2 years, return of vasomotion, and endothelial function. (Serruys et al., 2009)In our study, fifty patients were enrolled at Wadi El-Neel hospital catheterization laboratory between April 2015 and April 2016 and diagnosed as acute coronary syndrome. Data was collected using full history taking, thorough physical examination, twelve leads ECG, laboratory investigation and transthorcic echocardiography. Coronary angiography and PCI using BVS and post PCI assessment with quantitative coronary angiography (QCA) and intravascular ultrasound (IVUS) of target segment. Follow up with assessment of the anginal